Item type |
itemtype_ver1(1) |
公開日 |
2023-10-20 |
タイトル |
|
|
タイトル |
Latest classification of ependymoma in the molecular era and advances in its treatment: a review |
|
言語 |
en |
著者 |
Yamaguchi, Junya
Ohka, Fumiharu
Motomura, Kazuya
Saito, Ryuta
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利 |
|
|
言語 |
en |
|
権利情報 |
This is a pre-copyedited, author-produced version of an article accepted for publication in [Japanese Journal of Clinical Oncology] following peer review. The version of record [Junya Yamaguchi, Fumiharu Ohka, Kazuya Motomura, Ryuta Saito, Latest classification of ependymoma in the molecular era and advances in its treatment: a review, Japanese Journal of Clinical Oncology, Volume 53, Issue 8, August 2023, Pages 653–663, https://doi.org/10.1093/jjco/hyad056] is available online at: https://doi.org/10.1093/jjco/hyad056. |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
multimodal treatment |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
DNA methylation |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
molecular pathology |
キーワード |
|
|
主題Scheme |
Other |
|
主題 |
ependymoma |
内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Ependymoma is a rare central nervous system (CNS) tumour occurring in all age groups and is one of the most common paediatric malignant brain tumours. Unlike other malignant brain tumours, ependymomas have few identified point mutations and genetic and epigenetic features. With advances in molecular understanding, the latest 2021 World Health Organization (WHO) classification of CNS tumours divided ependymomas into 10 diagnostic categories based on the histology, molecular information and location; this accurately reflected the prognosis and biology of this tumour. Although maximal surgical resection followed by radiotherapy is considered the standard treatment method, and chemotherapy is considered ineffective, the validation of the role of these treatment modalities continues. Although the rarity and long-term clinical course of ependymoma make designing and conducting prospective clinical trials challenging, knowledge is steadily accumulating and progress is being made. Much of the clinical knowledge obtained from clinical trials to date was based on the previous histology-based WHO classifications, and the addition of new molecular information may lead to more complex treatment strategies. Therefore, this review presents the latest findings on the molecular classification of ependymomas and advances in its treatment. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1093/jjco/hyad056 |
収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1465-3621 |
書誌情報 |
en : Japanese Journal of Clinical Oncology
巻 53,
号 8,
p. 653-663,
発行日 2023-08
|
ファイル公開日 |
|
|
日付 |
2024-02-01 |
|
日付タイプ |
Available |